Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia

by Vandana Singh, Benzinga Editor

July 8, 2021 9:28 AM | 27 seconds read |

Vor Biopharma Inc VOR has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ.
Under the terms of the collaboration, Vor Biopharma will investigate the combination of Vor's engineered hematopoietic stem cell (eHSC) platform with one of Janssen's bi-specific antibodies for acute myeloid leukemia (AML).
The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.
Price Action: VOR shares closed at $18.15 on Wednesday.

Posted In: Biotech News Health Care Contracts Small Cap General Briefs myeloid leukemia

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.